Fresenius

Fresenius Kabi announced today it has launched Gadoterate Meglumine Injection, USP, a bioequivalent and therapeutic equivalent substitute for the contrast agent Dotarem®*. This is the second contrast agent introduced by Fresenius Kabi in the U.S. this year. 


Contrast agents are used by radiologists to enhance the visibility of internal structures in imaging procedures such as MRI or CT scans. Contrast agents are a new category of health care products for Fresenius Kabi.


*Dotarem® is a registered trademark of Guerbet.
 

Fresenius Kabi announced today it has launched Gadoterate Meglumine Injection, USP, a bioequivalent and therapeutic equivalent substitute for the contrast agent Dotarem®*. This is the second contrast agent introduced by Fresenius Kabi in the U.S. this year. 


Contrast agents are used by radiologists to enhance the visibility of internal structures in imaging procedures such as MRI or CT scans. Contrast agents are a new category of health care products for Fresenius Kabi.


*Dotarem® is a registered trademark of Guerbet.
 

Today is my first day as the new CEO of Fresenius. Our company has tremendous strengths and an exceptional team on which we can build, yet preparing Fresenius for the coming decades will require fundamental changes. In this video message, I share my thoughts on how we can create a Fresenius that all our stakeholders will benefit even more from. 

I am excited to be setting out on this journey with my colleagues! Together we will be creating the #FutureFresenius.

Sincerely,

xxx

October 3, 2022

Contact

Fresenius SE & Co. KGaA
Corporate Communications
Else-Kröner-Str. 1
61352 Bad Homburg v.d.H.
Germany
T +49 (0) 6172 608-2294
pr-fre@fresenius.com

Related Links

Management Board Group Overview

Michael Sen 2

Mediathek Company
Mediathek Topic
Mediathek Date
Mediathek Preview File
Mediathek Photo Print Version
Michael Sen in corporate headquarters of Fresenius
Mediathek Description Text

Michael Sen becomes Chairman of the Management Board of Fresenius (equivalent to President and CEO) on October 1, 2022. He will also continue in his role as Chairman of the Management Board of Fresenius Kabi, which he assumed in April 2021, until a successor is decided for this position.

Subscribe to